InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.42
(
0.00%
)
US TECH 100
17,688.00
(
-0.20%
)
Dow Jones
39,431.51
(
0.00%
)
Brent Oil
82.01
(
-1.44%
)
Bitcoin
61,814.46
(
-1.73%
)
Post# of 1643
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

bladerunner1717

Send PM Follow Ignore
Followers 38
Posts 5652
Boards Moderated 0
Alias Born 11/09/2003

bladerunner1717

Re: bladerunner1717 post# 1512

Tuesday, 06/15/2021 12:22:38 PM

Tuesday, June 15, 2021 12:22:38 PM

Post# of 1643
MGTA upgraded

Magenta upgraded to buy on stem cell transplant potential

BTIG has upgraded Magenta Therapeutics (NASDAQ:MGTA) from under review to buy and a price target of $20 (~43% upside).
Analyst Yun Zhong says that hematopoietic stem cell transplant ("HCST") market is growing with a strong unmet medical need.
Zhong notes that the number of HCST procedures doubled in the past 10 years, and more than 50,000 people per year have the procedure. However, many more could benefit but are not eligible.

Bladerunner
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up